We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+11.58%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$196M
(+8.3%)
Cap. Flow
-$299M
Cap. Flow
% of AUM
-11.74%
Top 10 Holdings %
Top 10 Hldgs %
37.92%
Holding
126
New
21
Increased
16
Reduced
23
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADPT
Adeptus Health Inc
ADPT
|
+$38.6M |
| 2 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$38M |
| 3 |
DBVT
DBV Technologies
DBVT
|
+$30M |
| 4 |
Humana
HUM
|
+$28.3M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$26.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$67.9M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$35.7M |
| 3 |
McKesson
MCK
|
+$27.5M |
| 4 |
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
|
+$27.4M |
| 5 |
AET
Aetna Inc
AET
|
+$25.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.67% |
| 2 | Financials | 3.21% |
| 3 | Industrials | 0.75% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $226M | 8.89% |
13,740,261
| – | – |
|
|
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
| $97.7M | 3.84% |
4,505,468
-1,000,560
| -18% | -$17.9M |
|
|
GWPH
3
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $90.8M | 3.57% |
991,800
+317,427
| +47% | +$26.7M |
|
|
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $86.7M | 3.41% |
3,673,727
+583,942
| +19% | +$14.4M |
|
|
AVXS
5
DELISTED
AveXis, Inc. Common Stock
AVXS
| $85M | 3.34% |
2,236,701
| – | – |
|
|
ADPT
6
DELISTED
Adeptus Health Inc
ADPT
| $82.7M | 3.25% |
1,600,861
+644,328
| +67% | +$38.6M |
|
|
XNPT
7
DELISTED
XENOPORT, INC.
XNPT
| $81.5M | 3.2% |
11,572,125
| – | – |
|
8
Vanda Pharmaceuticals
VNDA
$327M
| $67.1M | 2.64% |
5,996,691
| – | – |
|
9
Viatris
VTRS
$20.1B
| $57.9M | 2.28% |
1,339,334
-493,201
| -27% | -$21.8M |
|
|
DBVT
10
DBV Technologies
DBVT
$870M
| $56.9M | 2.23% |
174,323
+92,542
| +113% | +$30M |
|
11
Xencor
XNCR
$1.3B
| $55.6M | 2.19% |
2,930,486
-537,026
| -15% | -$7.36M |
|
|
WBA
12
DELISTED
Walgreens Boots Alliance
WBA
| $50.9M | 2% |
611,457
+100,000
| +20% | +$8.07M |
|
|
AAC
13
DELISTED
AAC Holdings
AAC
| $49.1M | 1.93% |
2,149,702
-145,234
| -6% | -$2.96M |
|
|
AET
14
DELISTED
Aetna Inc
AET
| $44.7M | 1.76% |
366,000
-225,465
| -38% | -$25.9M |
|
|
AERI
15
DELISTED
Aerie Pharmaceuticals
AERI
| $44.4M | 1.74% |
2,520,585
-111,897
| -4% | -$1.81M |
|
|
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
| $43.7M | 1.72% |
4,072,809
| – | – |
|
17
Editas Medicine
EDIT
$457M
| $41.7M | 1.64% |
1,709,400
| – | – |
|
18
DaVita
DVA
$15.2B
| $40.6M | 1.6% |
525,000
-297,000
| -36% | -$22.4M |
|
|
SYRS
19
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $38M | 1.49% |
+209,522
| New | +$38M |
|
20
eHealth
EHTH
$47.3M
| $37M | 1.46% |
2,640,609
-623,979
| -19% | -$7.57M |
|
|
ZLTQ
21
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $35.4M | 1.39% |
1,297,000
+192,583
| +17% | +$5.42M |
|
|
UAM
22
DELISTED
Universal American Corp
UAM
| $32.8M | 1.29% |
4,323,000
-962,500
| -18% | -$7.46M |
|
|
RLYP
23
DELISTED
RELYPSA INC COM
RLYP
| $30.9M | 1.21% |
1,670,383
-203,088
| -11% | -$3.57M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $29.8M | 1.17% |
8,361,069
-1,168,292
| -12% | -$3.81M |
|
|
TVTY
25
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $29.4M | 1.15% |
2,541,686
+66,299
| +3% | +$776K |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2016 Portfolio in Review
As of Q2 2016, Deerfield Management held 126 positions worth $2.54B, up 8.3% from $2.35B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $299M in Q2 2016, closing 19 positions and reducing 23 holdings. Its most notable exit was GSK, an estimated $67.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials and Industrials.
Against the trend, Deerfield Management opened a new position in Syros Pharmaceuticals, Inc. Common Stock worth $38M.
- Deerfield Management's largest Q2 2016 buy was Syros Pharmaceuticals, Inc. Common Stock: 209,522 shares worth $38M.
- Deerfield Management added most to Adeptus Health Inc in Q2 2016, an estimated $38.6M increase.
- Deerfield Management's biggest Q2 2016 reduction was Aetna Inc, cutting an estimated $25.9M.
- Deerfield Management fully exited GSK in Q2 2016, selling an estimated $67.9M.
- Deerfield Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2016.
- Deerfield Management opened 21 new positions and closed 19 in Q2 2016.
- Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $2.54B.
Based on Deerfield Management's 13F filing for Q2 2016, filed 15 Aug 2016.